GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » Net Current Asset Value

Luminex (Luminex) Net Current Asset Value : $3.26 (As of Mar. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Luminex Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Luminex's net current asset value per share for the quarter that ended in Mar. 2021 was $3.26.

The historical rank and industry rank for Luminex's Net Current Asset Value or its related term are showing as below:

LMNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.91   Med: 7.06   Max: 40.62
Current: 11.35

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Luminex was 40.62. The lowest was 2.91. And the median was 7.06.

LMNX's Price-to-Net-Current-Asset-Value is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 4.94 vs LMNX: 11.35

Luminex Net Current Asset Value Historical Data

The historical data trend for Luminex's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luminex Net Current Asset Value Chart

Luminex Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.96 3.96 3.31 2.79 4.41

Luminex Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 3.89 4.31 4.41 3.26

Competitive Comparison of Luminex's Net Current Asset Value

For the Medical Instruments & Supplies subindustry, Luminex's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luminex's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Luminex's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Luminex's Price-to-Net-Current-Asset-Value falls into.



Luminex Net Current Asset Value Calculation

Luminex's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2020 is calculated as

Net Current Asset Value Per Share(A: Dec. 2020 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(509.031-307.752-0-0)/45.6827
=4.41

Luminex's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2021 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2021 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(481.785-330.984-0-0)/46.2527
=3.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Luminex  (NAS:LMNX) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Luminex Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Luminex's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Luminex (Luminex) Business Description

Traded in Other Exchanges
N/A
Address
12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727
Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.
Executives
Harriss T Currie officer: SVP, Finance & CFO 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett officer: SVP, Global Sales & Cust Ops 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck director 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro director
Eric Shapiro officer: SR VP, GLOBAL MARKETING 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir director, officer: President & CEO 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii officer: SVP, Gen Counsel & Corp Secy 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild officer: SVP, Human Resources 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum director C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers officer: SVP, Global Mfg and Quality 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins officer: SR VP, R&D - US 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet director 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850

Luminex (Luminex) Headlines